Neurophet Q1 2026: Revenue decline, wider losses, raised 32B won

Q1 2026 consolidated revenue: 481M won (down 9.9% YoY)
Operating loss: -5.82B won (vs -4.83B in Q1 2025)
Net loss: -5.74B won (vs -4.83B)
Basic EPS: -480 won (vs -723 won, improved due to higher share count)
R&D expense: 2.13B won, 444.7% of sales
Cash & equivalents: 4.04B won (slight decrease from year-end)
Post-quarter: raised 32B won via convertible preferred shares and convertible bonds (board resolution Apr 10, settled Apr 20)
No dividends or treasury stock activity